A series of laboratory and clinical studies using josamycin (JM), a new macrolide antibiotic discovered in Japan, revealed the following results.
1)
Pneumococci, hemolytic streptococci and coagulase-positive
Staphylococcus aureus strains recently isolated from patients showed high sensitivity to JM, and
staphylococci resistant to com m only used antibiotics were also sensitive. Further many of
staphylococci resistant to EM, b e longing equally to macrolides, showed sensitivity to JM.
2) Detectable blood levels were demonstrated as long as 6 to 7 hours after oral administration of ca. 10. 0 to 20. 0 mg/kg, and their peaks were observed at the 3rd hour.
3) JM levels in mother's milk showed similar values to those in blood.
4) JM was, shown to be excreted into urine in its active state.
5) Good therapeutic results were obtained in most of 57 infantile acute infections belonging to 8 different diseases by daily oral dose of ca. 20 to 40 mg/kg, mostly of 30 mg/kg. JM wa s suggested to be effective in lung mycoplasmosis. The rate of effectiveness amounted to ab o u t 87% in total cases treated.
Pneumococci and
hemolytic streptococci isolated from medic a t ed patients were highly sensitive to JM. The cases infected with
staphylococci showing M I C of as high as 3. 12 mcg/ml or less responded well to JM.
6) Oral administration of ca. 20 to 30 mg/kg p er day for 10 days in children revealed no recognizable change in blood findings or liver function suspected to be due to medication.
抄録全体を表示